Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK2 | O00142 | 8/20 | 0.67 |
| ▸ | PYGM | P11217 | 3/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | TK1 | P04183 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7612600 | 1.00 | TK2 (0.67) | TK2PYGMCYP1A2CYP3A4TSHR | |
| SCHEMBL29519888 | 1.00 | TK2 (0.67) | TK2PYGMCYP1A2CYP3A4TSHR | |
| SCHEMBL7612603 | 1.00 | TK2 (0.67) | TK2PYGMCYP1A2CYP3A4TSHR | |
| SCHEMBL7612597 | 1.00 | TK2 (0.67) | TK2PYGMCYP1A2CYP3A4TSHR | |
| SCHEMBL1619757 | 0.91 | TK2 (0.81) | TK2PYGMCYP1A2CYP3A4TSHR | |
| SCHEMBL3071103 | 0.91 | TK2 (0.81) | TK2PYGMCYP1A2CYP3A4TSHR | |
| SCHEMBL2924506 | 0.91 | TK2 (0.81) | TK2PYGMCYP1A2CYP3A4TSHR | |
| SCHEMBL3071100 | 0.91 | TK2 (0.81) | TK2PYGMCYP1A2CYP3A4TSHR | |
| SCHEMBL16003484 | 0.91 | TK2 (0.81) | TK2PYGMCYP1A2CYP3A4TSHR | |
| SCHEMBL3191951 | 0.91 | TK2 (0.81) | TK2PYGMCYP1A2CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11685904-B2 | Recombinant vaccinia virus and methods of use thereof | Ignite Immunotherapy, Inc. (US) | 2023-06-27 | — | — | US | disclosed |
| EP-3923967-A1 | RECOMBINANT VACCINIA VIRUS AND METHODS OF USE THEREOF | Ignite Immunotherapy, Inc. (US) | 2021-12-22 | — | — | EP | disclosed |
| WO-2020165730-A1 | RECOMBINANT VACCINIA VIRUS AND METHODS OF USE THEREOF | Ignite Immunotherapy, Inc. (US) | 2020-08-20 | — | — | WO | disclosed |
| US-20200263145-A1 | RECOMBINANT VACCINIA VIRUS AND METHODS OF USE THEREOF | Ignite Immunotherapy, Inc. (US) | 2020-08-20 | — | — | US | disclosed |
| US-20020025296-A1 | Combined use of nucleoside analogues and gene transfection for tissue imaging and therapy | ALBERTA, GOVERNORS OF THE UNIVERSITY OF, THE (CA) | 2002-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020025296-A1 | Combined use of nucleoside analogues and gene transfection for tissue imaging and therapy | SLC29A1, SLC29A2, TK1 | TK2 26/4885PYGM 1427/4885CYP1A2 4515/4885 |
| US-11685904-B2 | Recombinant vaccinia virus and methods of use thereof | TP53, DCLRE1B, VAC14 | TK2 70/4885PYGM 975/4885CYP1A2 4458/4885 |
| US-20200263145-A1 | RECOMBINANT VACCINIA VIRUS AND METHODS OF USE THEREOF | TP53, DCLRE1B, VAC14 | TK2 70/4885PYGM 975/4885CYP1A2 4458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.